Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 14;16(1):786-794.
doi: 10.1515/med-2021-0252. eCollection 2021.

Clinical and prognostic features of MMP-2 and VEGF in AEG patients

Qing-Kang Zheng  1 , Qing Yin  2 , Nan Zhang  3 , Zhi-Gang Sun  4
Affiliations

Clinical and prognostic features of MMP-2 and VEGF in AEG patients

Qing-Kang Zheng et al. Open Med (Wars). .

Abstract

Adenocarcinoma of the esophagogastric junction (AEG) has been increased in recent years and has become a worldwide problem that seriously affects human health. The purpose of the study is to investigate the clinical and prognostic characteristics of the matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) expression in AEG patients. A total of 69 patients were enrolled in this study. The result showed that the high expression of MMP-2 was significantly associated with tumor differentiation (P < 0.05) and depth of invasion (pT, P < 0.05). The high expression of VEGF was significantly associated with pT (P < 0.05) and lymph node metastasis (pN, P < 0.05). There was a positive correlation between MMP-2 and VEGF expression (P < 0.01). The 5-year survival rate for the 69 AEG patients was 40.6% and it was significantly associated with tumor differentiation (P < 0.05), pN (P < 0.01), pTNM stage (P < 0.01), MMP-2 expression (P < 0.05), and VEGF expression (P < 0.05). Cox multivariate regression demonstrated that tumor differentiation and pN were independent factors for the 5-year survival rate. Our study showed that MMP-2 and VEGF could work synergistically in AEG development.

Keywords: MMP-2; VEGF; adenocarcinoma of the esophagogastric junction; immunohistochemistry.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Immunohistochemical staining of adenocarcinoma of the esophagogastric junction (AEG) tissue sections demonstrating Matrix metalloproteinase-2 (MMP-2) (Original magnification ×200). (a) AEG specimen with high expression of MMP-2. (b) AEG specimen with low expression of MMP-2. (c) The corresponding normal gastric tissue specimen with no MMP-2 expression (contrast). (d) The corresponding normal esophageal tissue specimen with no MMP-2 expression (contrast).
Figure 2
Figure 2
Immunohistochemical staining of adenocarcinoma of the esophagogastric junction (AEG) tissue sections demonstrating vascular endothelial growth factor (VEGF) (Original magnification ×200). (a) AEG specimen with high expression of VEGF. (b) AEG specimen with low expression of VEGF. (c) The corresponding normal gastric tissue specimen with no VEGF expression (contrast). (d) The corresponding normal esophageal tissue specimen with no VEGF expression (contrast).
Figure 3
Figure 3
(a) The Kaplan-Meier survival curve of 69 cases of AEG patients. (b) Survival curves of AEG patients with tumor differentiation. (c) Survival curves of AEG patients with negative or positive pN. (d) Survival curves of AEG patients with different pTNM. (e) Survival curves of AEG patients with low or high expression of MMP-2 expression. (f) Survival curves of AEG patients with low or high expression of VEGF expression.
See this image and copyright information in PMC

References

    1. Hatta W, Tong D, Lee YY, Ichihara S, Uedo N, Gotoda T. Different time trend and management of esophagogastric junction adenocarcinoma in three Asian countries. Dig Endosc. 2017;29(Suppl 2):18–25. 10.1111/den.12808. - DOI - PubMed
    2. Hatta W, Tong D, Lee YY, Ichihara S, Uedo N, Gotoda T. Different time trend and management of esophagogastric junction adenocarcinoma in three Asian countries. Dig Endosc. 2017;29(Suppl 2):18–25. doi: 10.1111/den.12808. - DOI - PubMed
    1. Liu K, Yang K, Zhang W, Chen X, Chen X, Zhang B, et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988-2012: a singleinstitution, high-volume experience in China. Ann Surg. 2016;263:88–95. 10.1097/SLA.0000000000001148. - DOI - PMC - PubMed
    2. Liu K, Yang K, Zhang W, Chen X, Chen X, Zhang B. et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988-2012: a singleinstitution, high-volume experience in China. Ann Surg. 2016;263:88–95. doi: 10.1097/SLA.0000000000001148. - DOI - PMC - PubMed
    1. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–9. 10.1046/j.1365-2168.1998.00940.x. - DOI - PubMed
    2. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–9. doi: 10.1046/j.1365-2168.1998.00940.x. - DOI - PubMed
    1. Hosoda K, Yamashita K, Katada N, Watanabe M. Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction. Gen Thorac Cardiovasc Surg. 2015;63:549–56. 10.1007/s11748-015-0575-2. - DOI - PubMed
    2. Hosoda K, Yamashita K, Katada N, Watanabe M. Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction. Gen Thorac Cardiovasc Surg. 2015;63:549–56. doi: 10.1007/s11748-015-0575-2. - DOI - PubMed
    1. Huang Q. Carcinoma of the gastroesophageal junction in Chinese patients. World J Gastroenterol. 2012;18:7134–40. 10.3748/wjg.v18.i48.7134. - DOI - PMC - PubMed
    2. Huang Q. Carcinoma of the gastroesophageal junction in Chinese patients. World J Gastroenterol. 2012;18:7134–40. doi: 10.3748/wjg.v18.i48.7134. - DOI - PMC - PubMed

LinkOut - more resources